Kymera Investor Day Presentation Deck slide image

Kymera Investor Day Presentation Deck

Criteria • Availability of ● Approaches ● Virtual Screen ● A Comprehensive Hit Finding Toolbox Rapidly Enables New Ligand Discovery Against All Target Classes structure or homology model DB ~8 million purchasable cpds Cloud enables screen < 24hrs Al to improve enrichment KYMERA H ● DEL Criteria High quality protein Ideal QC profile (single-species by SEC; <5% aggregation by DLS) ©2021 KYMERA THERAPEUTICS, INC. Criteria Availability of high quality (crystallization-grade) Ⓡ Fragment-Based Screen ● Approaches SPR, NMR X-ray LC/MS (covalent) ● protein Robust crystallization system Cysteine Covalent Screening Criteria Proteins have reactive cysteines • Approaches • Covalent fragment screening on recombinant protein • Whole cell covalent fragment screening KYMERA R&D DAY - December 16th, 2021 HTS Criteria Available high- throughput assay format Approaches Focused library Diversity set ● IM) ASMS Criteria • Availability of high- quality protein PAGE 92
View entire presentation